All In Biotech

Drug Trial Radar · NCT07944326

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients (RENAISSANCE): A Randomized, Placebo-controlled, Double Blinded, Multicenter Clinical Trial of Sotagliflozin Versus Placebo

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Apr 1, 2027

Primary completion

Oct 1, 2031

Study completion Mar 1, 2032

Sponsor

Lead sponsor
University of British ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); Lexicon Pharmaceuticals; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.

Conditions

  • Kidney Transplant Recipient

Interventions

  • SotagliflozinDrug

    Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.

  • PlaceboDrug

    Matching placebo will be administered for 3-4.5 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hierarchical Composite of All-Cause Mortality, Kidney Transplant Loss, Non-Fatal Stroke or Myocardial Infarction, Sustained 40% Decline in eGFR, Heart Failure Events, and Total eGFR SlopeTime frame: From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.
  2. Number of Participants Experiencing Serious Adverse EventsTime frame: From randomization to the end of the study (up to 4.5 years).
  3. Number of Participants Experiencing Adverse Events Leading to Permanent Study Drug DiscontinuationTime frame: From randomization to the end of the study (up to 4.5 years).
  4. Number of Participants Experiencing Study Drug-Related Adverse EventsTime frame: From randomization to the end of the study (up to 4.5 years).
  5. Number of Participants Experiencing Adverse Events of Special InterestTime frame: From randomization to the end of the study (up to 4.5 years).

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Minnesota

    Minneapolis, Minnesota

  • NewYork-Presbyterian / Weill Cornell Medical Center

    New York, New York

  • UNC Medical Center

    Chapel Hill, North Carolina

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • University of Alberta

    Edmonton, Alberta, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Kingston General Hospital

    Kingston, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • Centre de Recherche du CHUM Pavillon R

    Montreal, Quebec, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • CHU de Québec - Université Laval

    Québec, Quebec, Canada

  • St. Paul's Hospital

    Saskatoon, Saskatchewan, Canada

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Auckland City Hospital

    Auckland, New Zealand

  • Hospital del Mar

    Barcelona, Spain

  • University Hospitals Birmingham

    Birmingham, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

  • St George's University Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.